Tirzepatide, a once-weekly injectable prescription medication that copies two gut hormones, curbs appetite and improves blood-sugar control. For adults carrying excess weight, evidence for large, lasting weight loss and better blood sugar, blood pressure and blood fats is strong. Digestive side effects are common, part of the weight lost is muscle, and most benefit fades when the medication stops. For lean, healthy adults seeking longevity, it remains essentially untested. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track % change from own baseline | Expected to change: primary efficacy marker |
| Lean mass (DXA scan) | No established target; track change from own baseline | Safety check: excessive lean loss changes training, protein or dose |
| HbA1c | 4.0–5.6% (standard reference range) | Expected to change: blood-sugar control |
| Fasting glucose | 70–99 mg/dL (standard reference range) | Safety check: low values prompt diabetes-drug reduction |
| Triglycerides | 0–149 mg/dL (standard reference range) | Expected to change: lipid improvement |
| LDL cholesterol | 0–99 mg/dL (standard reference range) | Expected to change: modest reduction |
| eGFR and creatinine | 60 mL/min/1.73 m² or above (standard reference range) | Safety check: a fall during vomiting or diarrhea signals dehydration-related kidney injury |
| Urine albumin-to-creatinine ratio | Below 30 mg/g (standard reference range) | Expected to change: albumin leakage falls |
| ALT | 7–56 U/L (standard reference range) | Expected to change: falls as liver fat decreases |
| Lipase | 13–60 U/L (standard reference range; assay-specific) | Safety check: tested if severe abdominal pain occurs |
| Calcitonin | Men ≤8.4 ng/L, women ≤5.0 ng/L (standard reference range; assay-specific) | Safety check: optional thyroid C-cell screen |
| Bone mineral density (DXA scan) | No established target; track change from own baseline | Safety check: hip bone loss may occur |
| hsCRP | 0–3.0 mg/L (standard reference range) | Expected to change: inflammation marker falls |
| Blood pressure and resting heart rate | Readings below about 100/60 mm Hg prompt medication review | Safety check: blood pressure can drop below target and heart rate rises slightly |
Cadence: Baseline before starting; weight, blood pressure and side effects every 4 weeks during dose escalation; kidney function rechecked whenever vomiting or diarrhea is significant; laboratory tests at 3 months, then every 6–12 months; body composition and bone density every 12 months during substantial weight loss